Efficacy of Xiidra in Dry Eye Disease After Collagen Cross Linking
NCT ID: NCT05045053
Last Updated: 2021-09-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
40 participants
INTERVENTIONAL
2021-02-01
2022-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
CHED - Congenital Hereditary Endothelial Dystrophy: New Paradigm Shift in Therapy Using Topical Eye Drops
NCT04843839
A Clinical Study Evaluating the Safety and Efficacy of SI-614 Ophthalmic Solution in Patients With Dry Eye
NCT01558999
An Exploratory Crossover Clinical Trial to Compare the Activity of Reproxalap and Lifitegrast in a Dry Eye Disease Chamber
NCT05102409
Xiidra vs. Xiidra + Dextenza Treatment for Dry Eye Disease
NCT04413253
Cross-linked Hyaluronic Acid and Coenzyme Q10 in the Treatment of Dry Eye
NCT03074344
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
xiidra group
patients are treated with 0.5 % xiidra twice daily and artificial tears for 6 months after corneal collagen cross linking
Xiidra 5% Ophthalmic Solution
lifitegrast 0.5% ia applied twice daily after corneal collagen cross linking
control group
patient are treated with artificial tears for 6 months after corneal collagen cross linking in both groups
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Xiidra 5% Ophthalmic Solution
lifitegrast 0.5% ia applied twice daily after corneal collagen cross linking
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Benha University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Tarek Roshdy mohamed Mahgoub ELhamaky
assisatant professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tarek Elhamaky
Role: PRINCIPAL_INVESTIGATOR
Benha university faculty of medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
INMC
Abu Dhabi, , United Arab Emirates
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
TAREK R ELHAMAKY, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Hamaky17
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.